VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
| Autor: | Campone, Mario, Ma, Cynthia X., De Laurentiis, Michelino, Iwata, Hiroji, Hurvitz, Sara A., Wander, Seth Andrew, Danso, Michael A., Lu, Dongrui Ray, Perkins Smith, Julia, Liu, Yuan, Tran, Lana, Anderson, Sibyl, Hamilton, Erika P. |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS1122-TPS1122, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|